01.31.24
Michal Morrison Inc., a biotech skincare company, has appointed Dr. Gail K. Naughton PhD to its science advisory team and board of directors.
Michal Morrison Inc. launched its first product—Genesis βSTEM6 Molecular Serum—last spring after more than two decades of research in regenerative medicine and recent advances in stem cell science.
Naughton, a global leader in regenerative medicine for the past 35 years, has successfully developed significant cell-based therapeutics and bioengineered tissue technologies throughout her career. Her pioneering work in the field of tissue engineering and regenerative medicine combined with her business acumen has seen her take four products from concept, through FDA approval, to market launch as well as taking two companies to publicly traded NASDAQ listings, the company said.
Naughton, a global leader in regenerative medicine for the past 35 years, has successfully developed significant cell-based therapeutics and bioengineered tissue technologies throughout her career. Her pioneering work in the field of tissue engineering and regenerative medicine combined with her business acumen has seen her take four products from concept, through FDA approval, to market launch as well as taking two companies to publicly traded NASDAQ listings, the company said.
“I am honored to join the visionary scientists and the board at Michal Morrison Inc.,” said Naughton. “The company’s patented βSTEM6 technology represents an unprecedented achievement in biotech skincare. βSTEM6 is the only molecule of its kind validated by studies to support the skin’s own regenerative process. I am thrilled to be working with Dr. Michael Kahn PhD, and Dr. Fuqiang Ruan, the visionary scientists who developed βSTEM6 technology.”
From Histogen to San Diego State
Dr. Naughton spent more than 35 years extensively researching the tissue engineering process, holds over 140 US and foreign patents and has founded two regenerative medicine companies. She founded Histogen in 2007 to focus on the development of novel solutions based on the products of cells grown under simulated embryonic conditions. She is the inventor of the technology and through May of 2021 served in a variety of executive capacities including chairperson, CEO and chief scientific officer. She served as a scientific advisor for Histogen until June of 2023.
Naughton served as the Dean of the College of Business Administration at San Diego State University from August 2002 to June 2011. During her tenure, she established several novel scholastic programs including the world’s first PhD/MBA program. Prior to, she spent more than 15 years at Advanced Tissue Sciences, where she was the company’s co-founder and co-inventor of its core technology. During her tenure Dr. Naughton held a variety of key management positions, including president, chief operating officer, chief scientific officer and principal scientist.